



York and Scarborough
Teaching Hospitals
NHS Foundation Trust

Retinal Laser in Diabetic Retinopathy

Information for patients, relatives and carers

Ophthalmology Department

① For more information, please contact:

Nurse Practitioner, The York Hospital
Wigginton Road, York, YO31 8HE
Tel: 01904 726758

Or

Eye Clinic, Scarborough Hospital
Woodlands Drive, Scarborough, YO12 6QL
Tel: 01723 342055

Depending on where you are being treated

Contents	Page
Retinal laser in diabetics.....	2
Focal and grid laser	3
What are the benefits of having focal and grid laser treatment?	3
Are there any risks from having focal and grid laser treatment?	4
Panretinal Laser	5
What are the benefits of having panretinal laser treatment?	5
Are there any risks from panretinal laser treatment?	6
Tell us what you think of this leaflet	7
Teaching, training and research.....	7
Patient Advice and Liaison Service (PALS).....	7
Leaflets in alternative languages or formats	8

Retinal laser in diabetics

Retinal laser treatment is administered in out-patients. You will sit at a machine similar to the microscope you sit at during the examination of your eyes by the doctor. The laser treatment can take between 10 to 20 minutes.

Before treatment, you will be asked to sign a consent form (reference FYCON88-3 Focal and grid laser or FYCON90-3 Pan retinal laser). This is where you show you understand what is to be done and confirming that you wish to proceed.

Make sure that you discuss any concerns and to ask any questions you may have before signing the form. The form will be kept in your Patient Notes, and you will be given a copy for your own records.

Focal and grid laser

In diabetic eye disease there can be leakage from blood vessels around the macula (macula oedema), which is the area of the retina, which is responsible for fine vision. This leakage causes thickening or oedema of the retina and can reduce your central vision.

What are the benefits of having focal and grid laser treatment?

It has been shown that laser treatment to this area of leakage can reduce the risk of moderate visual loss by half (50%) at three years. However, there is a possibility that the laser treatment may not help.

In some patient's laser is unsuitable due to the very central location of leakage and in these patients' other modalities of treatment involving intravitreal drugs may be offered. The central retinal thickness has to be over 400 microns for the eye to be eligible for anti-VEGF injections under the NHS.

In some cases, laser may reduce the need for injections when the leakage is off centre.

Are there any risks from having focal and grid laser treatment?

- A central burn causing reduction or loss of central vision
- An enlarging laser scar causing a blind spot in the central vision
- A choroidal neovascular membrane formed by blood vessels growing from the deeper choroid into the retina around the laser scars (less than 1 in 100 cases)
- Fibrosis
- A small risk of failing the DVLA driving field

Many patients require more than one treatment and often up to three or four treatments. Patients are reviewed at approximately three to four months after this type of laser treatment.

Panretinal Laser

In diabetic eye disease there can be growth of new blood vessels. These blood vessels are not healthy and do not help the circulation in the eye. They can cause several problems including vitreous haemorrhage, raised intraocular pressure and most significantly, severe loss of vision.

What are the benefits of having panretinal laser treatment?

By carrying out laser treatment on the peripheral retina it has been shown that the risk of severe visual loss can be reduced by half (50%) at two years.

Are there any risks from panretinal laser treatment?

This laser treatment is not a guarantee that the new vessels will disappear or that visual loss will be prevented. There are potential side effects from this type of laser treatment:

- Haemorrhage
- Macula oedema in 19 out of 100 patients
- Transient loss of vision in 10 out of a 100 patients
- Loss of visual field
- Difficulty in adapting to the dark and night vision
- 10 to 40 out of 100 patients may fail DVLA tests after bilateral panretinal laser
- Fibrosis of the retina
- Inflammation

Patients often need more than one treatment session and will be reviewed approximately one month after the laser treatment.

Tell us what you think of this leaflet

We hope that you found this leaflet helpful. If you would like to tell us what you think, please contact:

Miss N Topping, Consultant Ophthalmologist,
The York Hospital, Wigginton Road, York, YO31 8HE or
telephone 01904 725588.

Teaching, training and research

Our Trust is committed to teaching, training and research to support the development of health and healthcare in our community. Healthcare students may observe consultations for this purpose. You can opt out if you do not want students to observe. We may also ask you if you would like to be involved in our research.

Patient Advice and Liaison Service (PALS)

PALS offers impartial advice and assistance to patients, their relatives, friends and carers. We can listen to feedback (positive or negative), answer questions and help resolve any concerns about Trust services.

PALS can be contacted on 01904 726262, or email yhs-tr.patientexperienceteam@nhs.net.

An answer phone is available out of hours.

Leaflets in alternative languages or formats

If you would like this information in a different format, including braille or easy read, or translated into a different language, please speak to a member of staff in the ward or department providing your care.

Patient Information Leaflets can be accessed via the Trust's Patient Information Leaflet website:
www.yorkhospitals.nhs.uk/your-visit/patient-information-leaflets/

Owner	Miss N Topping, Consultant Ophthalmologist
Date first issued	May 2004
Review Date	January 2027
Version	4 (issued January 2024)
Approved by	Medical Retina Group
Linked to consent form	FYCON88-3 Focal and Grid Laser v4 FYCON90-3 Panretinal Laser v4
Document Reference	PIL 253 v4
© 2024 York and Scarborough Teaching Hospitals NHS Foundation Trust. All Rights reserved.	